found that increased METTL3 expression promotes miR-196a expression and tumor progression via m6A modification (115).Additionally, Li et al., through a study of 1,057 NSCLC cases from the TCGA database, found that copy number variations in m6A regulators, such as deletions in FTO and YTHDC2, are associated with poor prognosis in NSCLC patients (183). This evidence concerns the gene METTL3 and neoplasm.